LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
Frequently asked questions
What sector does LSB (LSB) operate in?
LSB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is LSB (LSB) current stock price?
As of the latest data, LSB stock price is $0.63, with a previous close of $0.63.
What is LSB (LSB) current market capitalization?
LSB market cap is approximately 25.84 million.
What is LSB (LSB) Earnings Per Share (EPS)?
The trailing EPS is -$0.73.
Does LSB (LSB) pay dividends?
No. LSB does not pay a dividend.
What is LSB (LSB) beta (volatility) score?
LSB has a beta of 0.570, indicating lower volatility than the overall market.
Unfortunately, you do not have access to this data. Make sure you have an active subscription.
